Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01730144 · ClinicalTrials.gov registry record

Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults

A clinical trial of Normal Physiology, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
10
Enrollment target
1
Study location

NCT01730144: Completed study of Normal Physiology, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT01730144 is a study of Normal Physiology that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 10 participants, below the 1,292-participant average among 25 other Normal Physiology trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01730144, a study of Normal Physiology, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
10 participants
Enrollment target
1
Study location

Study Summary

Background: \- One form of the influenza vaccine is a nasal spray. It uses a live but weakened flu virus. Researchers want to better under how the live vaccine interacts with the body s immune system. They will test the nasal spray flu vaccine (called FluMist) against a saline (salt water) nasal spray. They will then look at blood and nasal cell samples to see how the vaccine affects these cells immune response. Objectives: \- To look at immune changes in nasal and blood cells in people who receive live flu vaccine. Eligibility: \- Healthy volunteers between 18 and 49 years of age. Design: * Participants will have five outpatient visits for this study. Each visit will last up to 2 hours. * At the first visit, participants will have a physical exam and medical history. They will give blood and urine samples. Nasal cell samples will also be collected. * A week later, participants will have either the nasal spray flu vaccine or a saline spray. They will know which spray they will receive. Blood samples will be collected. * Two days after the vaccination, they will have another physical exam. Blood and nasal cell samples will be collected. * At the final two visits (1 week and 1 month after the vaccination), more blood samples will be collected. * Those who had the saline spray will be able to have the actual vaccine spray at the last study visit. * The ratio of participants who receive vaccine to those who receive saline will be 4:1.

Conditions Studied

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2012-11-17
Est. Completion 2019-07-12

What the finished NCT01730144 record still lists

NCT01730144 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,292-participant average among 25 other Normal Physiology trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Normal Physiology appearing as the primary indexed condition, and to 0 interventions.

NCT01730144 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT01730144 about?

NCT01730144 is a clinical study titled "Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults". Background: \- One form of the influenza vaccine is a nasal spray. It uses a live but weakened flu virus. Researchers want to better under how the live vaccine interacts with the body s immune system. They will test the nasal spray flu vaccine (called FluMist) against a saline (salt water) nasal sp...

What is the current status of trial NCT01730144?

This trial is currently completed. The enrollment target is 10 participants. The study started on 2012-11-17. Estimated completion is 2019-07-12.

What conditions does trial NCT01730144 study?

This clinical trial studies the following conditions: Normal Physiology.

Who is sponsoring clinical trial NCT01730144?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01730144 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Normal Physiology

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01730144's enrollment target sits among peer trials

10 26th of 25 the lowest of 25 other Normal Physiology trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Normal Physiology trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01730144, the US trial registry maintained by the National Library of Medicine. NCT01730144 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.